Human Papillomavirus - 1st Edition - ISBN: 9780128144572

Human Papillomavirus

1st Edition

Proving and using a Viral Cause for Cancer

Editors: Xavier Bosch David Jenkins
Paperback ISBN: 9780128144572
Imprint: Academic Press
Published Date: 1st August 2019
Page Count: 200
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Human Papillomavirus: Proving and using a Viral Cause for Cancer presents a steady and massive accumulation of evidence about the role of HPV and prevention of HPV-induced cancer, and the role and personal commitment of many scientists of different backgrounds in establishing the global relevance of this virus. This exercise involved years of personal commitment to proving or disproving an idea that aroused initial scepticism, and still has difficult implications for some conservative religious groups, although not for most people worldwide. It remains one of the big successes of medicine that exploited both established medical science dating back to the nineteenth century and new molecular genetic science at a time of great transition in medicine and remains a model for the application of new science to clinical and preventive medicine

Key Features

  • A comprehensive up to date review of the role of HPV in cancer by those involved in its study
  • Presents the way in which evidence on the role and utility of HPV based prevention has been accumulated over almost 40 years by a growing band on international clinical and basic scientists and epidemiologists
  • Gives a series of vignettes of individual scientists involved in the development of the science of HPV and cancer at different stages and their reasons for involvement and experiences of this research and its issues


Clinical and scientific virology and cancer research, public health, diagnostic and pharmaceutical industries, modern medical history and sociology. Graduate level scientists in virology, molecular biology, pathology, screening, vaccines and epidemiology and public health

Table of Contents

Section 1: Early questions and their slow answers
Introduction: Implications and responses to a possible specific infectious cause for a solid cancer, approaches to proving the role of HPV, and exploring its potential uses against conventional medical practice. (DJ, XB)
Cervical and other cancers now associated with HPV prior to recognition of HPV in cervical cancer. (DJ)
Cervical screening and its basis in ideas of precancer in classical microscopic pathology. (Christine Bergeron, Tom Wright )
The "discovery" of HPV I6 in cervical cancer and studies of its transforming role, P53 and pRB. (Lutz Gissmann, Dennis McCance)
Growing numbers of carcinogenic papillomaviruses and understanding of their differences (Robbie Burke, Mark Schiffmann)
The impact of HPV on conventional morphological pathology of cancer and precancer. Bethesda classification, molecular markers relating morphology to molecular mechanisms. (Mark Stoller, Magnus von Knebel Doeberitz, John Doorbar)
The proof of causality in humans (XB, Nubia Munoz, Eduardo Franco)
Progression from infection to cancer (Barbara Moscicki, K Syrjanen)
Sexuality and HPV: sexual transmission, male role, (Barbara Moscicki, Diane Harper, J Palefsky)
Genital warts (Charles Lacey, Nuria Guimera)
HPV and non-cervical cancer (KV Shah)
Immune responses, and antibodies to HPV, making viral antigens (Lutz Gissmann, Ian Frazer, John Schiller)
Developing and standardising HPV tests (Atilla Lorincz, Chris Meijer, Wim Quint, Cosette Wheeler, Marc Arbyn)
HPV and non-HPV pathways to cancer (DJ, Wim Quint)

Section 2: Prevention of cancer and HPV infection
Introduction: Evidence-based medicine, HPV and cancer prevention (DJ, XB)
Triage of women with low-grade smear abnormalities and HPV testing, HC1 and 2, GP5+/6+, ALTS trial, Netherlands, other trials. (Mark Schiffmann, Chris Meijer, Jack Cuzick)
Primary screening by HPV testing (Chris Meijer, R Sankaranyanan)
Prophylactic vaccines, proving their value and the role and limitations of the pharmaceutical industry and its regulators, safety and efficacy. (DJ, Laura Koutsky, Jorma Paavonen)
Modelling disease, prevention and cost-effectiveness – a developing process, different types of models, what does cost-effectiveness mean? (Johannes Berkhof, Walter Kinney)
Changing global concerns about screening and vaccination (Tom Broker, Sylvia de Sanjose)


No. of pages:
© Academic Press 2019
Academic Press
Paperback ISBN:

About the Editor

Xavier Bosch

Senior Consultant to the Cancer Epidemiology Research Program and Director of International Affairs at the Catatan Institute of Oncology - Director of the e-oncologia - Co-Director of the the IARC / ICO Information Centre on HPV and Cancer, Catalan Institute of Oncology | Cancer Epidemiology Research Program | Granvia de L'Hospitalet 199-203 | 08908 L'Hospitalet de Llobregat (Barcelona, Catalonia, Spain)

Affiliations and Expertise

Senior Consultant, Cancer Epidemiology Research Program and Director of International Affairs, Catatan Institute of Oncology

David Jenkins

Senior Researcher. Practitioner and author and Emeritus Professor in Pathology, University of Nottingham, UK

Affiliations and Expertise

Emeritus Professor in Pathology, University of Nottingham, UK

Ratings and Reviews